Anti-PD-1 Antibody Combined With Autologous DC and NK Cells in the Treatment of Digestive Carcinoma

NCT05461235 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

1

Enrollment

OTHER

Sponsor class

Conditions

PD-1 Antibody
DC-Cell
NK-Cell
Gastrointestinal Tumours

Interventions

DRUG: Pembrolizumab
DRUG: Nivolumab
DRUG: Sintilimab
DRUG: Toripalimab
DRUG: Camrelizumab
DRUG: Tislelizumab
BIOLOGICAL: NK-Cell or DC-Cell

Sponsor

China Medical University, China